IVT mRNA is formulated into lipid nanoparticle vaccines using a cell-free production pipeline

author: Namit Chaudhary , Drew Weissman and Kathryn A. Whitehead

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts.
Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research is required to optimize mRNA design, intracellular delivery and applications beyond SARS-CoV-2 prophylaxis. In this Review, we describe the technologies that underlie mRNA vaccines, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles. We also overview the pipeline of mRNA vaccines against various infectious disease pathogens and discuss key questions for the future application of this breakthrough vaccine platform.

mRNA production flow

3’-deoxyadenosine Abogen Cansino biologics Conference Cordycepin Coronavirus Vaccine COVID-19 dNTPs Exhibition GMP site Immorna investment LNP mRNA NTPs Nucleosides Nucleotides Oligo Oligonucleotides Phosphoramidite Phosphoramidites RNA sequences Solid-phase synthesis synthesis of oligonucleotides Vaccine